Identification of enzymes responsible for rifalazil metabolism in human liver microsomes

被引:15
作者
Mae, T
Inaba, T
Konishi, E
Hosoe, K
Hidaka, T
机构
[1] Kaneka Corp, Takasago Res Labs, Takasago, Hyogo 6768688, Japan
[2] Univ Toronto, Fac Med, Dept Pharmacol, Toronto, ON M5S 1A8, Canada
关键词
D O I
10.1080/004982500406408
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1. The major metabolites of rifalazil in human are 25-deacetyl-rifalazil and 32-hydroxy-rifalazil. Biotransformation to these metabolites in pooled human liver microsomes, cytosol and supernatant 9000g (S9) fractions was studied, and the enzymes responsible for rifalazil metabolism were identified using inhibitors of esterases and cytochromes P450 (CYP). 2. The 25-deacetylation and 32-hydroxylation of rifalazil occurred in incubations with microsomes or S9 but not with cytosol, indicating that both the enzymes responsible for rifalazil metabolism were microsomal. K-m and V-max of the rifalazil-25-deacetylation in microsomes were 6.5 mu M and 11.9 pmol/min/mg with NADPH, and 2.6 mu M and 6.0 pmol/ min/mg without NADPH, indicating that, although rifalazil-25-deacetylation did not require NADPH, NADPH activated it. Rifalazil-32-hydroxylation was NADPH dependent, and its K-m and V-max were 3.3 mu M and 11.0 pmol/min/mg respectively. 3. Rifalazil-25-deacetylation in microsomes was completely inhibited by diisopropyl fluorophosphate, diethyl p-nitrophenyl phosphate and eserine, but not by p-chloromercuribenzoate or 5,5'-dithio-bis(2-nitrobenzoic acid), indicating that the enzyme responsible for the rifalazil-25-deacetylation is a B-esterase. 4. Rifalazil-32-hydroxylation in microsomes was completely inhibited by CYP3A4-specific inhibitors (fluconazole, ketoconazole, miconazole, troleandomycin) and drugs metabolized by CYP3A4 such as cyclosporin A and clarithromycin, indicating that the enzyme responsible for the rifalazil-32-hydroxylation is CYP3A4.
引用
收藏
页码:565 / 574
页数:10
相关论文
共 34 条
[2]   ABSORPTION, DISPOSITION AND PRELIMINARY METABOLIC PATHWAY OF C-14 RIFABUTIN IN ANIMALS AND MAN [J].
BATTAGLIA, R ;
PIANEZZOLA, E ;
SALGAROLLO, G ;
ZINI, G ;
BENEDETTI, MS .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1990, 26 (06) :813-822
[3]   ACTIVITY OF KRM-1648 ALONE OR IN COMBINATION WITH ETHAMBUTOL OR CLARITHROMYCIN AGAINST MYCOBACTERIUM-AVIUM IN BEIGE MOUSE MODEL OF DISSEMINATED INFECTION [J].
BERMUDEZ, LE ;
KOLONOSKI, P ;
YOUNG, LS ;
INDERLIED, CB .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (08) :1844-1848
[4]   URINARY METABOLITES OF RIFABUTIN, A NEW ANTIMYCOBACTERIAL AGENT, IN HUMAN VOLUNTEERS [J].
COCCHIARA, G ;
BENEDETTI, MS ;
VICARIO, GP ;
BALLABIO, M ;
GIOIA, B ;
VIOGLIO, S ;
VIGEVANI, A .
XENOBIOTICA, 1989, 19 (07) :769-780
[5]   IN-VITRO AND IN-VIVO ANTIBACTERIAL ACTIVITIES OF KRM-1648 AND KRM-1657, NEW RIFAMYCIN DERIVATIVES [J].
FUJII, K ;
TSUJI, A ;
MIYAZAKI, S ;
YAMAGUCHI, K ;
GOTO, S .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (05) :1118-1122
[6]   IN-VITRO AND IN-VIVO ACTIVITIES OF THE BENZOXAZINORIFAMYCIN KRM-1648 AGAINST MYCOBACTERIUM-TUBERCULOSIS [J].
HIRATA, T ;
SAITO, H ;
TOMIOKA, H ;
SATO, K ;
JIDOI, J ;
HOSOE, K ;
HIDAKA, T .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (10) :2295-2303
[7]   Pharmacokinetics of KRM-1648, a new benzoxazinorifamycin, in rats and dogs [J].
Hosoe, K ;
Mae, T ;
Konishi, E ;
Fujii, K ;
Yamashita, K ;
Yamane, T ;
Hidaka, T ;
Ohashi, T .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (12) :2749-2755
[8]   Identification and antimicrobial activity of urinary metabolites of a rifamycin derivative in dog [J].
Hosoe, K ;
Mae, T ;
Yamashita, K ;
Fujii, K ;
Yamane, T ;
Hidaka, T ;
Ohashi, T .
XENOBIOTICA, 1996, 26 (03) :321-332
[9]   Metabolism of rifabutin in human enterocyte and liver microsomes: Kinetic parameters, identification of enzyme systems, and drug interactions with macrolides and antifungal agents [J].
Iatsimirskaia, E ;
Tulebaev, S ;
Storozhuk, E ;
Utkin, I ;
Smith, D ;
Gerber, N ;
Koudriakova, T .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1997, 61 (05) :554-562
[10]   HIV protease inhibitors, saquinavir, indinavir and ritonavir: Inhibition of CYP3A4-mediated metabolism of testosterone and binzoxazinorifamycin, KRM-1648, in human liver microsomes [J].
Inaba, T ;
Fischer, NE ;
Riddick, DS ;
Stewart, DJ ;
Hidaka, T .
TOXICOLOGY LETTERS, 1997, 93 (2-3) :215-219